Evolent Health Inc Class A EVH 深 沪
等待开盘 02-11 09:30:00 美东时间
2.84
+0.110
+4.03%
华盛通- 最 高2.905
- 今 开2.73
- 成交量 94.69万股
- 最 低 2.688
- 昨 收 2.73
- 总市值 3.17亿
- 52周最高 12.065
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 2.685
- 委 比 39.13%
- 总股本 1.12亿
- 历史最高 39.779
- 量 比 1.26
- 振 幅 7.95%
- 历史最低 2.685
- 每 手 1
- 风险率 2.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Deep Dive Into Evolent Health Stock: Analyst Perspectives (11 Ratings)
In the latest quarter, 11 analysts provided ratings for Evolent Health (NYSE:EV...
02-02 20:00
BTIG Maintains Buy on Evolent Health, Lowers Price Target to $10
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $10.
02-02 18:40
V.F. Corp beats top-line and bottom-line estimates; initiates Q4 and FY26 outlook
V.F. Corp press release (VFC): Q3 Non-GAAP EPS of $0.58 beats by $0.14. Revenue of $2.88B (+1.8% Y/Y) beats by $120M. Q4'26 and FY'26 Financial Outlook1 Q4'26: Revenue flat to +2% C$ vs. LY Adjusted O...
01-28 19:06
V.F. Corp Q3 2026 Earnings Preview
V.F. Corp (VFC) is scheduled to announce Q3 earnings results on Wednesday, January 28th, before market open.The consensus EPS Estimate is $0.44 (-29.0% Y/Y) and the consensus Revenue Estimate is $2.76...
01-27 22:48
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
The Analyst Verdict: Evolent Health In The Eyes Of 9 Experts
Analysts' ratings for Evolent Health (NYSE:EVH) over the last quarter vary from...
01-06 21:01
Citizens Maintains Market Outperform on Evolent Health, Lowers Price Target to $10
Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $11 to $10.
01-06 20:55
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex condition...
01-03 05:15
